Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

SNX-111 development re-scheduled

Sep. 27, 1996

Sanofi reports tachykinin antagonists

Sep. 27, 1996

Glutamate inhibitor progresses through the pipeline

Sep. 20, 1996

Another series of mGluR antagonists from Lilly

Sep. 20, 1996

Metabotropic glutamate receptor antagonists from Lilly

Sep. 20, 1996

Metabotropic glutamate antagonists from Novo Nordisk

Sep. 20, 1996

Forest prepares submission for Alzheimer's disease product

Sep. 20, 1996

Bayer patents new compounds for CNS disorders

Sep. 20, 1996

Antiemetic 5-HT3 antagonist launched in Japan

Sep. 20, 1996

Roquinimex in MS

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...